Education
About Us
Working with TipRanks
Follow Us
FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
Total Valuation
FibroBiologics, Inc. has a market cap or net worth of $25.34M. The enterprise value is $25.97M.
Market Cap$25.34M
Enterprise Value$25.97M
Share Statistics
FibroBiologics, Inc. has 41,889,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,889,140
Owned by Insiders14.18%
Owned by Institutions1.95%
Financial Efficiency
FibroBiologics, Inc.’s return on equity (ROE) is -4.08 and return on invested capital (ROIC) is -103.38%.
Return on Equity (ROE)-4.08
Return on Assets (ROA)-0.68
Return on Invested Capital (ROIC)-103.38%
Return on Capital Employed (ROCE)-3.69
Revenue Per Employee0.00
Profits Per Employee-858.54K
Employee Count13
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of FibroBiologics, Inc. is ―. FibroBiologics, Inc.’s PEG ratio is 0.14.
PE Ratio―
PS Ratio0.00
PB Ratio24.04
Price to Fair Value24.04
Price to FCF-5.44
Price to Operating Cash Flow-1.44
PEG Ratio0.14
Income Statement
In the last 12 months, FibroBiologics, Inc. had revenue of 0.00 and earned -11.16M in profits. Earnings per share was -0.34.
Revenue0.00
Gross Profit-573.00K
Operating Income-13.74M
Pretax Income-11.16M
Net Income-11.16M
EBITDA-13.74M
Earnings Per Share (EPS)-0.34
Cash Flow
In the last 12 months, operating cash flow was -14.94M and capital expenditures -366.00K, giving a free cash flow of -15.30M billion.
Operating Cash Flow-14.94M
Free Cash Flow-15.30M
Free Cash Flow per Share-0.37
Dividends & Yields
FibroBiologics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.54
52-Week Price Change-61.73%
50-Day Moving Average0.63
200-Day Moving Average1.29
Relative Strength Index (RSI)51.82
Average Volume (3m)488.86K
Important Dates
FibroBiologics, Inc. upcoming earnings date is Nov 18, 2025, After Close (Confirmed).
Last Earnings DateJul 31, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
FibroBiologics, Inc. as a current ratio of 1.12, with Debt / Equity ratio of 1253.02%
Current Ratio1.12
Quick Ratio1.12
Debt to Market Cap0.14
Net Debt to EBITDA0.25
Interest Coverage Ratio-686.85
Taxes
In the past 12 months, FibroBiologics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
FibroBiologics, Inc. EV to EBITDA ratio is -4.54, with an EV/FCF ratio of -5.16.
EV to Sales0.00
EV to EBITDA-4.54
EV to Free Cash Flow-5.16
EV to Operating Cash Flow-5.24
Balance Sheet
FibroBiologics, Inc. has $8.85M in cash and marketable securities with $10.78M in debt, giving a net cash position of $1.93M billion.
Cash & Marketable Securities$8.85M
Total Debt$10.78M
Net Cash$1.93M
Net Cash Per Share$0.05
Tangible Book Value Per Share$0.08
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for FibroBiologics, Inc. is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside1512.90% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast43.68%